SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C

Giadi Sebastiani, Philippe Halfon, Laurent Castera, Stanislas Pol, David L. Thomas, Alessandra Mangia, Vito Di Marco, Mario Pirisi, Mihai Voiculescu, Maria Guido, Marc Bourliere, Franco Noventa, Alfredo Alberti

Research output: Contribution to journalArticle

Abstract

The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use. The aim of this study was to validate the recently described sequential algorithm for fibrosis evaluation (SAFE) biopsy, which detects significant fibrosis (≥F2 by METAVIR) and cirrhosis (F4) by combining the AST-to-platelet ratio index and Fibrotest-Fibrosure, thereby limiting liver biopsy to cases not adequately classifiable by noninvasive markers. Hepatitis C virus (HCV) patients (2035) were enrolled in nine locations in Europe and the United States. The diagnostic accuracy of SAFE biopsy versus histology, which is the gold standard, was investigated. The reduction in the need for liver biopsies achieved with SAFE biopsy was also assessed. SAFE biopsy identified significant fibrosis with 90.1% accuracy (area under the receiver operating characteristic curve = 0.89; 95% confidence interval, 0.87-0.90) and reduced by 46.5% the number of liver biopsies needed. SAFE biopsy had 92.5% accuracy (area under the receiver operating characteristic curve = 0.92; 95% confidence interval, 0.89-0.94) for the detection of cirrhosis, obviating 81.5% of liver biopsies. A third algorithm identified significant fibrosis and cirrhosis simultaneously with high accuracy and a 36% reduction in the need for liver biopsy. The patient's age and body mass index influenced the performance of SAFE biopsy, which was improved with adjusted Fibrotest-Fibrosure cutoffs. Two hundred two cases (9.9%) had discordant results for significant fibrosis with SAFE biopsy versus histology, whereas 153 cases (7.5%) were discordant for cirrhosis detection; 71 of the former cases and 56 of the latter cases had a Fibroscan measurement within 2 months of histological evaluation. Fibroscan confirmed SAFE biopsy findings in 83.1% and 75%, respectively. Conclusion: SAFE biopsy is a rational and validated method for staging liver fibrosis in hepatitis C with a marked reduction in the need for liver biopsy. It is an attractive tool for large-scale screening of HCV carriers.

Original languageEnglish (US)
Pages (from-to)1821-1827
Number of pages7
JournalHepatology
Volume49
Issue number6
DOIs
StatePublished - Jun 2009

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this

    Sebastiani, G., Halfon, P., Castera, L., Pol, S., Thomas, D. L., Mangia, A., Di Marco, V., Pirisi, M., Voiculescu, M., Guido, M., Bourliere, M., Noventa, F., & Alberti, A. (2009). SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology, 49(6), 1821-1827. https://doi.org/10.1002/hep.22859